Rafarma Pharmaceuticals Inc. [Wy] (RAFA) 0.2600 $RAFA
Rafarma Pharmaceuticals (OTC:RAFA) Announces Significant Cash Flow Improvement Through Restructuring
PR Newswire - Thu Apr 10, 8:10AM CDT
In response to shareholder inquiries, CEO Dave Anderson offers further comment on the improved financial position of Rafarma:
Restructuring offers Assurance of Rafarma Pharmaceuticals' Improved Financial Future
PR Newswire - Wed Apr 02, 10:00AM CDT
Rafarma Pharmaceuticals Inc. (OTC RAFA) is pleased to announce the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank), Russia's premier development bank. Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.
Rafarma Pharmaceuticals (OTC:RAFA) Announces Cooperative Agreement with the St. Petersburg Academy of Pharmaceutical Chemistry
PR Newswire - Wed Feb 05, 7:00AM CST
On February 3, 2014, ZAO Rafarma management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.
Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez
PR Newswire - Tue Jan 28, 10:02AM CST
Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.
Rafarma Pharmaceuticals Announces a $1.2 Million Private Placement
PR Newswire - Thu Dec 12, 3:05PM CST
Rafarma Pharmaceuticals (OTC:RAFA), announces a $1.2 million private placement.
Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
PR Newswire - Mon Nov 11, 8:35AM CST
Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.
Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
PR Newswire - Thu Sep 19, 8:15AM CDT
Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.
Rafarma Pharmaceuticals, Inc. (RAFA) Enters New Distribution Agreement with Amber Pharma Distribution Group
PR Newswire - Tue Sep 10, 8:05AM CDT
Rafarma Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.
Rafarma Pharmaceuticals, Inc. (RAFA) New Dialysis Research and Development Center to Join Rafarma in Making Terbuny Russia's New Biotech Hub
Marketwire - Fri Aug 02, 10:10AM CDT
The success of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced.
Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Marketwire - Thu Jul 25, 8:40AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:
Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors
Marketwire - Wed Jul 17, 9:08AM CDT
The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:
Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Marketwire - Tue Jul 16, 12:48PM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.
Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
Marketwire - Fri Jul 05, 9:28AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
GlobeNewswire - Thu Jun 06, 8:18AM CDT
Rafarma Pharmaceuticals, Inc. (the "Company"
(Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.
Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Marketwire - Wed Apr 10, 7:00AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Marketwire - Mon Apr 08, 7:02AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
PR Newswire - Mon Feb 04, 8:15AM CST
Rafarma Pharmaceuticals, Inc. (the "Company" OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.
Rafarma Pharmaceuticals (OTC:RAFA) Announces Significant Cash Flow Improvement Through Restructuring
PR Newswire - Thu Apr 10, 8:10AM CDT
In response to shareholder inquiries, CEO Dave Anderson offers further comment on the improved financial position of Rafarma:
Restructuring offers Assurance of Rafarma Pharmaceuticals' Improved Financial Future
PR Newswire - Wed Apr 02, 10:00AM CDT
Rafarma Pharmaceuticals Inc. (OTC RAFA) is pleased to announce the complete restructuring of its existing EUR 90,000,000.00 loan with VNeshconombank (VEBank), Russia's premier development bank. Terms and conditions of the restructured loan include a 3-year deferment, or holiday, on all principal and interest payments thus greatly enhancing the financial stability of the company.
Rafarma Pharmaceuticals (OTC:RAFA) Announces Cooperative Agreement with the St. Petersburg Academy of Pharmaceutical Chemistry
PR Newswire - Wed Feb 05, 7:00AM CST
On February 3, 2014, ZAO Rafarma management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.
Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez
PR Newswire - Tue Jan 28, 10:02AM CST
Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.
Rafarma Pharmaceuticals Announces a $1.2 Million Private Placement
PR Newswire - Thu Dec 12, 3:05PM CST
Rafarma Pharmaceuticals (OTC:RAFA), announces a $1.2 million private placement.
Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
PR Newswire - Mon Nov 11, 8:35AM CST
Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.
Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
PR Newswire - Thu Sep 19, 8:15AM CDT
Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.
Rafarma Pharmaceuticals, Inc. (RAFA) Enters New Distribution Agreement with Amber Pharma Distribution Group
PR Newswire - Tue Sep 10, 8:05AM CDT
Rafarma Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.
Rafarma Pharmaceuticals, Inc. (RAFA) New Dialysis Research and Development Center to Join Rafarma in Making Terbuny Russia's New Biotech Hub
Marketwire - Fri Aug 02, 10:10AM CDT
The success of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced.
Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Marketwire - Thu Jul 25, 8:40AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:
Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors
Marketwire - Wed Jul 17, 9:08AM CDT
The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:
Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Marketwire - Tue Jul 16, 12:48PM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.
Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
Marketwire - Fri Jul 05, 9:28AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
GlobeNewswire - Thu Jun 06, 8:18AM CDT
Rafarma Pharmaceuticals, Inc. (the "Company"
(Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone. Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Marketwire - Wed Apr 10, 7:00AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Marketwire - Mon Apr 08, 7:02AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
PR Newswire - Mon Feb 04, 8:15AM CST
Rafarma Pharmaceuticals, Inc. (the "Company"
OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation. 
